Kura Oncology Inc (NASDAQ:KURA) – Svb Leerink increased their FY2019 earnings per share estimates for Kura Oncology in a research note issued to investors on Tuesday, November 5th. Svb Leerink analyst J. Chang now anticipates that the company will post earnings per share of ($1.50) for the year, up from their prior forecast of ($1.51). Svb Leerink also issued estimates for Kura Oncology’s Q4 2019 earnings at ($0.38) EPS.
A number of other brokerages have also recently issued reports on KURA. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Kura Oncology in a report on Friday, August 2nd. Deutsche Bank began coverage on shares of Kura Oncology in a report on Thursday, July 18th. They issued a “buy” rating and a $28.00 price objective for the company. ValuEngine cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Monday, October 21st. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Kura Oncology in a report on Thursday, September 5th. Finally, BidaskClub upgraded shares of Kura Oncology from a “strong sell” rating to a “sell” rating in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.11.
Shares of NASDAQ:KURA opened at $15.53 on Friday. The company has a market cap of $672.35 million, a P/E ratio of -9.03 and a beta of 2.57. Kura Oncology has a 12-month low of $11.01 and a 12-month high of $21.42. The company’s fifty day moving average is $14.92 and its two-hundred day moving average is $16.88. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.03.
A number of institutional investors have recently added to or reduced their stakes in the business. Eagle Asset Management Inc. lifted its position in Kura Oncology by 1.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 2,075,747 shares of the company’s stock worth $31,489,000 after acquiring an additional 31,878 shares during the last quarter. Alps Advisors Inc. lifted its position in Kura Oncology by 12.7% during the 3rd quarter. Alps Advisors Inc. now owns 90,112 shares of the company’s stock worth $1,367,000 after acquiring an additional 10,184 shares during the last quarter. SG Americas Securities LLC lifted its position in Kura Oncology by 1,393.4% during the 3rd quarter. SG Americas Securities LLC now owns 103,838 shares of the company’s stock worth $1,575,000 after acquiring an additional 96,885 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Kura Oncology during the 3rd quarter worth $114,000. Finally, California Public Employees Retirement System lifted its position in Kura Oncology by 46.4% during the 3rd quarter. California Public Employees Retirement System now owns 45,954 shares of the company’s stock worth $697,000 after acquiring an additional 14,554 shares during the last quarter. 84.97% of the stock is owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: Derivative
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.